Supplementary Figures 1_9 from PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
Year: 2023
Type: supplementary-materials
Abstract: Figure S1: The PI3K inhibitor buparlisib inhibits AKT phosphorylation and cell growth and induces cell cycle arrest and apoptosis in BRAF-mutant metastatic melanoma cell lines Figure S2: The PI3K inhibitor buparlisib inhibits AKT phosphorylation and cell growth and induces cell cycle arrest and apoptosis in NRAS-mutant metastatic melanoma cell lines Figure S3: Investigating the effects of buparlisib when combined with a MEK or BRAF inhibitor Figure S4: The PI3K inhibitor buparlisib inhibits cell growth in short-term brain melanoma cell lines Figure S5: Fibroblasts are resistant to the PI3K inhibitor buparlisib Figure S6: Buparlisib inhibits exponential growth pattern of brain metastasis in nude mice Figure S7: Histological sections of the brain melanoma tumors provide evidence of hemorrhages, necrosis and tumor regression Figure S8: Buparlisib downregulates pAKT and inhibits proliferation but does not induce apoptosis in brain metastases of nude mice Figure S9: Buparlisib downregulates PLEKHA5 in brain metastases of nude mice
Authors: Heike Niessner, Jennifer Schmitz, Ghazaleh Tabatabai, Andreas M. Schmid, Carsten Calaminus, Tobias Sinnberg, Benjamin Weide, Thomas K. Eigentler, Claus Garbe, Birgit Schittek, Leticia Quintanilla-Fend, Benjamin Bender, Marion Mai, Christian Praetorius, Stefan Beissert, Gabriele Schackert, Michael H. Muders, Matthias Meinhardt, Gustavo B. Baretton, Reinhard Dummer, Keith Flaherty, Bernd J. Pichler, Dagmar Kulms, Dana Westphal, Friedegund Meier
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361929140